G1, bad control; G2, 5 mg/kg Avastin on day time 1, 8 and 15; G3, 10 mg/kg AP25 every day; G4, 10 mg/kg Fusion protein every five days; G5, 10 mg/kg Fusion protein every three days; G6, 10 mg/kg Fusion protein every two days; G7, 40 mg/kg Fusion protein every five days; G8, 40 mg/kg Fusion protein every three days; G9, 40 mg/kg Fusion protein every two days (*p 0

G1, bad control; G2, 5 mg/kg Avastin on day time 1, 8 and 15; G3, 10 mg/kg AP25 every day; G4, 10 mg/kg Fusion protein every five days; G5, 10 mg/kg Fusion protein every three days; G6, 10 mg/kg Fusion protein every two days; G7, 40 mg/kg Fusion protein every five days; G8, 40 mg/kg Fusion protein every three days; G9, 40 mg/kg Fusion protein every two days (*p 0.05, **p 0.01). Open in a separate window Figure 6 Tumor inhibition rate in the 23rd day time after PSG4R administration. anti-tumor effect of PSG4R was then evaluated on HCT-116 nude mice xenograft model. And the pharmacokinetics properties of PSG4R were investigated in rats. The results showed that PSG4R could inhibit the growth of xenografts of human being colon cancer cell collection HCT-116 in nude mice by intravenous administration of 40 mg/kg once every two days. The half-life time of PSG4R was 56.270 15.398 h. This study showed the building Canrenone of AP25-Fc fusion protein could significantly prolong the half-life of AP25 while retaining its anti-tumor activity, which provides Canrenone a new direction for new drug development of AP25. experiments proved that it could effectively inhibit human being breast malignancy and colon cancer development with an effect equivalent to the chemical drug docetaxel 2,3. The research on the mechanism of action of AP25 showed that it could inhibit angiogenesis by inhibiting the proliferation, migration and tubular formation of vascular endothelial cells, therefore exerting its anti-tumor activity and directly inhibits the Canrenone growth of tumor cells 4. However, as a small molecular polypeptide having a molecular excess weight of 2.53 kDa, the half-life time of AP25 is only about 50 minutes, which greatly limits its clinical software 5. At present, chemical modification and the fusion with a large protein are the most often used method to extend the half-life of proteins or polypeptides. The most common techniques are Fc fusion proteins, serum albumin fusion proteins, and transferrin fusion proteins 7,8. Fc-fusion proteins refer to the fusion of a functional protein with the Fc fragment of an antibody from the genetic executive technology. This fusion strategy not only retains the biological activity of practical proteins, but also stretches the half-life time, improves the stability, and facilitates the manifestation, purification and detection of the fusion proteins 9,10. More than a dozen Fc-fusion protein drugs have been commercialized, with annual sales of more than 10 billion US dollars. In this study, four AP25-Fc fusion proteins with different sequences and linkers were designed and indicated. The fusion protein with high anti-tumor activity was screened out through experiments, and then the anti-tumor activity and pharmacokinetic guidelines were evaluated and sequenced after amplification. The correct plasmid was then transiently transfected into HEK293 cells and cultured inside a shaking bed of 37 ?C, 8% CO2 and 120 rpm for 5 days. The supernatants of cell tradition medium, cell lysate supernatants and cell lysate precipitate were collected, respectively. The prospective protein was recognized by SDS-PAGE and Western blot. The supernatant of HEK293 cells was loaded into Protein A affinity chromatography column (1 ml) and the column was pre-equilibrated with 10 column quantities of equilibrium buffer (20 mM Tris, 500 mM NaCl, pH 8.0). The circulation rate was modified to 2 mg/mL. The column was then washed with 5 column quantities of equilibrium buffer and eluted with 0.1 M Glycine (pH 3.0). The desired peaks were collected, dialyzed against PBS (pH 7.4) and preserved for further experiments. HUVEC migration assay Transwell top chambers were coated having a thin film of serum-free matrigel and placed into 24-well plate. HUVEC cells were cultured in endothelial cell medium (ECM) supplemented with 5% fetal bovine serum (FBS) and 1% endothelial cell growth Rabbit Polyclonal to Vitamin D3 Receptor (phospho-Ser51) product (ECGS) at 37 ?C and 5% CO2. After trypsinization, HUVEC cells were diluted to 1 1 108 cells/L with serum-free ECM and 100 L of cells suspension was added to each chamber. The chambers were then supplied with 100 L sample solution which includes the fusion protein (0.1, 0.2, 0.4, 0.8 or 1.6 mol/L), AP25 (0.2, 0.4 or 0.8 mol/L), the positive control Avastin (0.17 mol/L), PBS solvent control, respectively. 100 L serum-free ECM was used as a negative control. The migration of HUVEC cells was stimulated by adding 0.6 mL ECM comprising 5% FBS and 1% ECGS into 24-well.